"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. B-cell Non-Hodgkin Lymphoma - Overview
3. Executive Summary
4. B-cell Non-Hodgkin Lymphoma: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. B-cell Non-Hodgkin Lymphoma: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. CG-806 – Aptose Biosciences
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. APG-2575 – Ascentage Pharma Group Corporation, Ltd.
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. JNJ-67856633 – Janssen Global Services, LLC,
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. B-cell Non-Hodgkin Lymphoma: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. B-cell Non-Hodgkin Lymphoma: Additional Key Insights
7.1. Epidemiology Overview: B-cell Non-Hodgkin Lymphoma
7.2. Current Market Scenario: B-cell Non-Hodgkin Lymphoma Therapeutics
8. B-cell Non-Hodgkin Lymphoma: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.